Research Article

The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People

Maria H. Nilsson, PhD,1,2,* Gro Gujord Tangen, PhD,4,5 Sebastian Palmqvist, MD, PhD,2,3 Danielle van Westen, MD, PhD,6,7,* Niklas Mattsson-Carlsgren, MD, PhD,2,8 Erik Stomrud, MD, PhD,2,3 and Oskar Hansson, MD, PhD2,3,*

1Department of Health Sciences, Faculty of Medicine, Lund University, Sweden. 2Clinical Memory Research Unit, Faculty of Medicine, Lund University, Sweden. 3Memory Clinic, Skåne University Hospital, Malmö, Sweden. 4Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tonsberg, Norway. 5Department of Geriatric Medicine, Oslo University Hospital, Norway. 6Diagnostic Radiology, Department of Clinical Sciences, Lund University, Sweden. 7Image and Function, Skane University Hospital, Lund, Sweden. 8Wallenberg Center for Molecular Medicine, Lund University, Sweden.

*Address correspondence to: Maria H. Nilsson, PhD, Department of Health Sciences, Faculty of Medicine, Lund University, Lund, Sweden. E-mail: maria_h.nilsson@med.lu.se

Received: October 12, 2019; Editorial Decision Date: May 31, 2020

Decision Editor: Jay Magaziner, MSHyg, PhD

Abstract

Background: This study aimed to investigate whether white matter lesions (WML), β-amyloid-, and tau pathologies are independently associated with mobility, dual tasking, and dynamic balance performance in older nondemented individuals.

Methods: We included 299 older people (mean, SD, age: 71.8, 5.6 years) from the Swedish BioFINDER study, whereof 175 were cognitively unimpaired and 124 had mild cognitive impairment (MCI). In multivariable regression analyses, dependent variables included mobility (Timed Up & Go [TUG]), dual tasking (TUG with a simultaneous subtraction task, that is, TUG-Cog, as well as dual task cost), and balance (Figure-of-eight). The analyses were controlled for age, sex, education, diagnosis (ie, MCI), and comorbidity (stroke, diabetes, and ischemic heart disease). Independent variables included WML volume, and measures of β-amyloid (abnormal cerebrospinal fluid [CSF] Aβ42/40 ratio) and tau pathology (CSF phosphorylated tau [p-tau]).

Results: Multivariable regression analyses showed that an increased WML volume was independently associated with decreased mobility, that is, TUG (standardized β = 0.247; p < .001). Tau pathology was independently associated with dual tasking both when using the raw data of TUG-Cog (β = 0.224; p = .003) and the dual-task cost (β = −0.246; p = .001). Amyloid pathology was associated with decreased balance, that is, Figure-of-eight (β = 0.172; p = .028). The independent effects of WML and tau pathology were mainly observed in those with MCI, which was not the case for the effects of amyloid pathology on balance.

Conclusions: Common brain pathologies have different effects where WML are independently associated with mobility, tau pathology has the strongest effect on dual tasking, and amyloid pathology seems to be independently associated with balance. Although these novel findings need to be confirmed in longitudinal studies, they suggest that different brain pathologies have different effects on mobility, balance, and dual-tasking in older nondemented individuals.

Keywords: Biomarkers, Dementia, Magnetic resonance imaging, Postural balance, Difficulty walking
WML as well as Aβ and tau aggregates can be reliably detected in vivo (5,6).

Alzheimer’s disease (AD) is the most common cause of dementia among older adults. Aβ pathology is a sign of AD, which can be measured using the cerebrospinal fluid (CSF) Aβ42/40 ratio or by using positron emission tomography (PET), that is, amyloid-PET, which have high agreement (6,7). Tau pathology is the second neuropathological hallmark of AD, which can be measured using either CSF phosphorylated tau (p-tau) or tau-PET (8). Small vessel disease is detected and quantified using magnetic resonance imaging (MRI) (5). In AD, widespread amyloid pathology develops one to three decades before symptom onset and is not on its own strongly associated with cognitive impairment (9). Widespread neocortical tau pathology occurs later in the disease and is associated with development of MCI and dementia (10–12). When it comes to WML, such brain changes have been shown to be associated with both cognitive decline and worse motor performance in older people, including balance impairments and falls (13).

Previous PET studies have shown an association between Aβ burden and decreased gait performance in older people without dementia (14–18), but none of these addressed tau pathology. Recent studies showed that tau pathology is more associated with cognitive impairment than WML or Aβ pathology (12,19,20), which highlights the importance of also addressing tau pathology. Although gait and mobility are related, they are not interchangeable constructs, which also applies for balance performance. Importantly, previous studies (17,18,21–28) that addressed mobility and balance did not simultaneously consider WML, Aβ-, and tau pathology. Such knowledge is needed to gain an increased understanding of their independent effects. One way of assessing mobility is by using the Timed Up & Go (TUG) test (29). In studies that used TUG, WML detected by MRI were associated with decreased mobility in older people without dementia (21,22). PET studies that focused on Aβ and mobility (ie, TUG) showed conflicting results (18,24). A recent study that used CSF Aβ42 showed no significant correlation with mobility; nor did they find an association between CSF p-tau and mobility (25). In studies that focused on balance impairments, WML were associated with both balance impairments and falls (26–28). A PET study showed an association between Aβ pathology and declined static balance time in standing among cognitively unimpaired older persons (17).

There is limited knowledge of how tau pathology relates to mobility and balance performance in older people without dementia, and studies are needed that include WML as well as Aβ- and tau pathology.

The dual-task paradigm can reveal subtle motor impairments that cannot be detected during single-task test conditions. When interested in the cognitive-motor interference, the dual-task paradigm involves a motor task and a concurrent cognitive task (30). Two studies reported that WML were associated with slower dual task gait speed in older people without cognitive complaints (31,32), but another study reported contradictory results (21). None of these studies addressed Aβ- and tau pathology. There is limited and conflicting evidence on how CSF biomarkers (Aβ and tau) relate to dual tasking (25,33). The latter two studies had relatively small sample sizes (N ≤ 90), and they included persons with dementia. Importantly, they did not simultaneously take into account different CSF biomarkers by using multivariable analyses; nor did they include WML (25,33). This warrants further studies with larger sample sizes that can identify independent effects.

This study aimed to investigate whether WML, amyloid-, and tau pathology are independently associated with mobility, dual tasking, and dynamic balance performance in older nondemented people with and without MCI. Amyloid pathology was determined with the CSF Aβ42/40 ratio, and tau pathology was measured with CSF p-tau in agreement with the research framework of the U.S. National Institute on Aging–Alzheimer’s Association guidelines (34).

Our a priori hypotheses were that WML are independently associated with mobility and balance whereas tau pathology is independently associated with decreased dual-task performance. The latter hypothesis is based on that tau pathology is more associated with cognitive impairment than WML or Aβ pathology (12,19,20), and we will investigate dual-task performance that address cognitive–motor interference. In relation to amyloid pathology, we had a hypothesis-free approach.

Method
This cross-sectional study is part of the larger longitudinal Swedish BioFINDER study (www.biofinder.se). In the current study, participants were included if they had undergone a physical therapy assessment that addressed mobility, dual tasking, and balance. These assessments were done in 299 participants out of 591 in the larger BioFINDER study (Malmö, Sweden).

Participants
The study population included 77 cognitively normal older individuals (recruited from the population-based Malmö Diet Cancer Study (35)) and 222 nondemented patients with cognitive complaints enrolled consecutively at one memory outpatient clinic in Sweden.

Inclusion criteria for cognitively normal older people were (i) age ≥ 65 y, (ii) Mini-Mental State Examination (MMSE) 28–30 points at the screening visit, (iii) absence of cognitive symptoms as evaluated by a physician, (iv) not fulfilling the criteria of MCI or any dementia disorder, and (v) fluent in Swedish. Exclusion criteria included the following: (i) significant neurological or psychiatric disease (eg, stroke, Parkinson disease, multiple sclerosis, and major depression), (ii) significant systemic illness making participation difficult, or (iii) significant alcohol or substance abuse.

The inclusion criteria for patients with cognitive complaints were (i) cognitive symptoms, (ii) age 60–80 y, (iii) MMSE 24–30 points, (iv) not fulfilling the criteria for any dementia disorder, and (v) fluent in Swedish. The exclusion criteria were (i) cognitive impairment that without doubt could be explained by another condition (other than prodromal dementia), (ii) significant systemic illness making participation difficult, or (iii) significant alcohol or substance abuse. This rendered a sample of 222 nondemented people with cognitive complaints. They were classified as having either subjective cognitive decline (SCD, n = 98) or MCI (n = 124, of which 90 [73 %] had amnestic MCI and 34 [27 %] had nonamnestic MCI). The classification was based both on a neuropsychological battery (the following cognitive domains were included: verbal ability, visuospatial construction, episodic memory, and executive functions) and the clinical assessment of a senior neuropsychologist. In agreement with U.S. National Institute on Aging–Alzheimer’s Association guidelines, persons who were cognitively normal and those with SCD were included in the cognitively unimpaired group (34), resulting in 173 cognitively unimpaired participants and 124 participants...
with MCI. Participants’ characteristics are presented in Table 1. For the total sample (N = 299), the mean MMSE score was 27.9 (SD 1.8). The corresponding mean values for those who were cognitively unimpaired were 28.7 (SD 1.3) versus 26.8 (SD 1.8) for those with MCI.

**Table 1. Participants’ Characteristics and Missing Data, N = 299**

|                                | Total Sample | Cognitively Unimpaired | Mild Cognitive Impairment |
|--------------------------------|--------------|------------------------|--------------------------|
|                                | N = 299      | Miss, n                | n = 175                  | Miss, n |
| Age (y), mean (SD)             | 71.8 (5.6)   | –                      | 72.5 (5.6)               | –       |
| Sex (women), n (%)             | 142 (47.5)   | –                      | 86 (49.1)                | –       |
| Education (y), mean (SD)       | 11.8 (3.3)   | 3                      | 12.2 (3.4)               | –       |
| Comorbidity: stroke/diabetes/heart disease (yes), n | 27/32/39 | 0/1/1 | 10/19/17 | – | 17/13/22 | 0/1/1 |
| Timed Up & Go, ie, TUG, (s), mean (SD) | 11.6 (3.9) | 4 | 11.0 (2.8) | 2 | 12.4 (4.9) | 2 |
| TUG-Cog (s), mean (SD)         | 21.9 (18.9)  | 14*                    | 18.3 (10.6)              | 5       |
| Dual task cost (%), mean (SD)  | −90.2 (145.8) | 15 | −67.9 (82.0) | 6 | −123.0 (202.7) | 9 |
| Figure-of-eight (s), mean (SD) | 19.2 (10.5)  | 4†                     | 17.6 (6.9)               | 1       |
| WML (total volume, mL), mean (SD) | 18.0 (21.9) | 22 | 14 (16.8) | 10 | 23.7 (26.8) | 12 |
| p-tau (ng/L), mean (SD)        | 58.8 (23.9)  | 20                     | 54.5 (20.6)              | 16      |
| CSF Aβ42/40 (pathological, <0.878), n (%) | 111 (40.1) | 22 | 42 (26.4) | 16 | 69 (58.5) | 6 |

Notes: Miss, missing values; WML, white matter lesions; p-tau, phosphorylated tau; Aβ, β amyloid. TUG-Cog, ie, TUG with a simultaneous subtraction task.

†Two did not manage the Figure-of-eight.

Assessments by the Physical Therapist

The TUG assesses functional mobility and includes the following tasks: to rise from a chair, walk 3 m, turn around, and walk back to sit down again (29). The participant’s regular footwear was used and customary walking aid, but no physical assistance was given. Two trials were conducted: (i) TUG in comfortable gait speed and (ii) TUG in comfortable gait speed with a simultaneous serial subtraction task by 3 (starting: 100–3), that is, TUG-Cog. No instruction was given whether the participant should prioritize the motor and/or the cognitive task. The time (s) to complete each TUG trial was registered. Timing commenced when the participant's back was leaving the back of the chair and stopped when the buttock reached the seat of the chair. For each individual, the dual-task cost (%) was calculated by using the recommended formula (36): ([simple-task gait value − dual-task gait value]/simple-task gait value) × 100. In this study, the dual-task cost value (%) reflects how an increased cognitive load affects mobility. Negative values reflect that mobility is negatively influenced by the cognitive task.

The Figure-of-eight was developed as a balance task; it is stripped to the floor as two circles that are open in the intersection (37,38). In the current study, each inner circle had a diameter of 157 cm. Outer lines were stripped, which created a walking path of 10 cm. The participant initiated the test at the top (facing a counterclockwise direction), and the instruction was to step within the two stripes and complete walking the eight. No walking aids were allowed; five participants were therefore excluded in this test. One trial was conducted. The total time for completion was registered as well as number of oversteps, that is, steps where half of the foot was placed outside the lines. The total time of the Figure-of-eight was chosen as the dependent variable since it is more reliable than oversteps (38).

The test order was as follows: TUG (29); TUG-Cog; and Figure-of-eight (37,38). Two experienced physical therapists conducted the assessments, and all assessments were video recorded according to a standardized protocol. To eliminate minor discrepancies between the two assessors, the current ratings and timing were based on the video recordings retrospectively. A digital stopwatch was used when timing the tasks.

CSF Sampling/Analysis and MRI

Lumbar puncture and CSF handling followed a structured protocol as previously described (39). CSF Aβ42 and Aβ40 were analyzed using Euroimmun ELISAs (EUROIMMUN AG, Lübeck, Germany) and p-tau181 was analyzed using Innotest ELISA (Fujirebio Gent, Belgium). Due to the biomodal distribution the CSF Aβ42/Aβ40 ratio mixture modeling was used to identify an unbiased cutoff for abnormal Aβ accumulation (<0.878), as previously described (40,41).

MR imaging was performed at the same Siemens Trio 3 T system in all individuals and included transversal T2 FLAIR and a high-resolution isotropic MPRAGE. Automated segmentation of WML using the LST toolbox implemented in SPM8, generated a total lesion volume (mL), here named “WML volume,” for each individual (42).

Statistical Analyses

Pearson (r) and Spearman’s correlation coefficients (r) were used to study the relationships among the independent variables in order to detect any multicollinearity. The following independent variables were considered: WML volume, CSF p-tau, and CSF Aβ42/40 (1 = abnormal, <0.878).

Associations between each dependent variable and independent variables (WML, CSF p-Tau, and CSF Aβ42/40) were analyzed in a series of univariable regression models. Linear regression analyses were used for all dependent variables: TUG, TUG-Cog, dual-task cost, and for the total time of the Figure-of-eight. The simple regression analyses are presented in Supplementary File S1.
For the total sample, this was followed by multivariable regression analyses that included only one brain pathology, including controlling for age (y), sex (1 = woman), education (y), sample (1 = MCI), and comorbidity (Table 2). Data on comorbidity included dichotomous (No/Yes) variables in relation to stroke, diabetes, and ischemic heart disease.

In the following step, the multivariable analyses included controlling factors (ie, age, sex, education, sample, and comorbidity) and different brain pathologies (ie, WML volume, CSF p-tau, and CSF Aβ42/40), which were simultaneously entered (Table 3). That is, independent variables (ie, brain pathologies) were included regardless of their \( p \) value in the simple regression analyses, that is, in order to not leave out a potential confounding factor. The models were not reduced (ie, manually removing variables based on their \( p \) value) since the aim was not to provide prediction models but to gain an increased understanding of the independent association between pathology and mobility, dual tasking and balance, respectively. For multivariable linear regression analyses, residuals were inspected graphically as a validation of each model.

Multivariable analyses were rerun for those who were cognitively unimpaired or who had MCI, respectively (Tables 4–5). These analyses were controlled for age, sex, education, and comorbidity.

All statistical analyses were performed using SPSS Windows 24.0 (IBM SPSS Inc., Chicago, IL, USA).

### Results

Descriptive data and missing data are reported in Table 1, and simple regression analyses are presented in Supplementary File S1.

Multivariable regression analyses that included one brain pathology (controlling for age, sex, education, diagnosis, and comorbidity: stroke, diabetes, and ischemic heart disease) are presented in Table 2. Increased WML volume was the only variable significantly associated with mobility, that is, more WML were associated with an increased time to complete TUG (standardized beta, ie, \( \beta = 0.249; p < .001 \)). Although WML volume was not significantly associated with dual tasking, there was a trend in relation to TUG-Cog (\( \beta = 0.117; p = .078 \)) but not for the dual-task cost (\( \beta = −0.026; p = .700 \)). Higher CSF p-tau was associated with dual tasking, which applied both for TUG-Cog (\( \beta = 0.186; p = .003 \)) and the dual-task cost (\( \beta = −0.219; p = .001 \)). An abnormal CSF Aβ42/40 ratio was associated with an increased dual-task cost by 40% (\( \beta = −0.134; p = .043 \)), whereas Aβ was not associated with TUG-Cog (\( p = .104 \)). In addition, the CSF Aβ42/40 ratio was associated with dynamic balance, that is, Figure-of-eight (\( \beta = 0.164; p = .011 \)). This was not the case for WML volume (\( p = .319 \)) or tau pathology (\( p = .162 \)).

### Table 2. Multivariable Analyses (Total Sample); Each Controlled for Age, Sex, Education, Diagnosis, and Comorbidity

| DV | Mobility | Dual Tasking | Balance |
|----|----------|--------------|---------|
|    | TUG (s)  | TUG-Cog (s)  | Dual Task Cost (%) | Figure-of-Eight (s) |
| Independent variables | B (95% CI) \( \beta \); \( p \) value | B (95% CI) \( \beta \); \( p \) value | B (95% CI) \( \beta \); \( p \) value | B (95% CI) \( \beta \); \( p \) value |
| 1. WML volume, mL | 0.040 (0.020, 0.061) 0.249; | 0.090 (−0.010, 0.190) 0.117; | −0.155 (−0.944, 0.635) −0.026; | 0.034 (−0.033, 0.100) 0.066; |
| 2. p-tau, ng/L | −0.015 (−0.033, 0.004) −0.099; | 0.145 (0.049, 0.242) 0.186; | −1.38 (−2.16, −0.591) −0.219; | 0.001 |
| 3. CSF Aβ42/40 (1 = abnormal) | −0.012 (−1.09, 0.727) −0.026; | 3.95 (−0.821, 8.71) 0.105; | −39.9 (−78.6, −1.24) −0.134; | 0.043 |
|    | .693    | .104         | .043               | .111               |

**Notes:** DV, dependent variables; TUG, Timed Up & Go; TUG-Cog, TUG with a simultaneous subtraction task; WML, White matter lesions; p-tau, phosphorylated tau; CSF, cerebrospinal fluid; Aβ, amyloid. Multivariable analyses (1–3) included one brain pathology, ie, WML, p-tau, or CSF Aβ42/40; controlled for age, sex, education, diagnosis, and comorbidity. For dichotomous independent variables: 0, reference category. Dual task cost (%): \( \left( \frac{\text{TUG} − \text{TUG-Cog}}{\text{TUG}} \right) \times 100 \).

### Table 3. Multivariable Analyses (Total Sample); Controlled for Different Brain Pathologies, Age, Sex, Education, Diagnosis, and Comorbidity

| DV | Mobility | Dual Tasking | Balance |
|----|----------|--------------|---------|
|    | TUG (s) \( n = 251 \) | TUG-Cog (s) \( n = 240 \) | Dual Task Cost (%) \( n = 240 \) | Figure-of-Eight (s) \( n = 247 \) |
| WML volume, mL | 0.028 (−0.016, 0.179) 0.109; | 0.081 (−0.016, 0.179) 0.109; | −0.121 (−0.912, 0.670) −0.021; | 0.050 (−0.020, 0.121) 0.096; |
| p-tau, ng/L | −0.127 (−0.234, −0.021) −0.072; | 0.152 (0.054, 0.250) 0.224; | −1.32 (−2.11, −0.532) −0.246; | 0.004 (−0.066, 0.075) 0.009; |
| CSF Aβ42/40 (1 = abnormal) | 0.438 (−4.34, 5.21) 0.014; | 0.438 (−4.34, 5.21) 0.014; | −2.23 (−4.08, 3.63) −0.009; | 3.86 (0.413, 7.30) 0.172; |
|    | .857    | .909         | .028               | .011               |

**Notes:** DV, dependent variables; TUG, Timed Up & Go; TUG-Cog, TUG with a simultaneous subtraction task; WML, White matter lesions; p-tau, phosphorylated tau; CSF, cerebrospinal fluid; Aβ, amyloid. For dichotomous independent variables: 0, reference category. Dual task cost (%): \( \left( \frac{\text{TUG} − \text{TUG-Cog}}{\text{TUG}} \right) \times 100 \).
Multivariable analyses that involved the total sample (controlled for age, sex, education, diagnosis, and comorbidity) and simultaneously including WML, CSF p-tau, and CSF Aβ42/40 are presented in Table 3. Dependent variables were mobility (ie, TUG), dual tasking (TUG-Cog and dual-task cost, respectively), and balance (Figure-of-eight). WML volume was the only variable that was independently associated with mobility, that is, TUG (standardized beta, ie, β = 0.247; p < .001). CSF p-tau was the only variable independently associated with dual tasking, which applied both for the raw data of TUG-Cog (β = 0.224; p = .003) and the dual-task cost (β = −0.246; p = .001). An abnormal CSF Aβ42/40 ratio was the only variable significantly associated with decreased balance, that is, Figure-of-eight (β = 0.172; p = .028).

The independent effect of WML on mobility was significant among those with MCI (β = 0.365; p < .001), but it was not significant (p = .385) among those who were cognitively unimpaired (Table 4). The same pattern was shown in relation to the effect of tau pathology on dual tasking. CSF p-tau was independently associated with TUG-Cog (β = 0.326; p = .003) and the dual-task cost (β = −0.366; p = .001) among those with MCI, which was not the case (p ≥ .559) among those who were cognitively unimpaired (Tables 4–5). An abnormal CSF Aβ42/40 ratio was no longer significantly associated with balance, that is, among cognitively unimpaired (β = 0.176; p = .073) and those with MCI (β = 0.154; p = .207; Table 5).

### Discussion

This study provides novel knowledge by using multivariable analyses that take into account WML as well as markers of Aβ- and tau pathology in relation to mobility, dual tasking, and balance performance. This allowed studying independent effects of different common brain pathologies. In the total sample, we found that WML volume was independently associated with decreased mobility, and tau pathology was independently associated with dual tasking, whereas Aβ pathology was independently associated with dynamic balance in older persons without dementia. These findings might reflect the temporal evolution of Aβ- and tau pathology, where Aβ pathology precedes tau pathology by decades and that tau pathology is more associated with cognitive impairment than Aβ pathology (9–12,20).

The independent effects of WML and tau pathology were mainly observed in cases with MCI, which is interesting considering that these pathologies are associated with cognitive symptoms (12,19,20). On the contrary, amyloid pathology and balance tended to be associated in cognitively unimpaired, which makes sense considering that amyloid pathology develops about 20 y before MCI in AD (9).

### Table 4. Multivariable Regression Analyses with TUG or TUG-Cog as Dependent Variables in Cognitively Unimpaired and MCI, Respectively

| DV | Cognitively Unimpaired* | MCI* |
|----|-------------------------|------|
| n = 149 | n = 102 | n = 145 | n = 95 |
| WML volume, ml | B (95% CI) β; p value | B (95% CI) β; p value | B (95% CI) β; p value | B (95% CI) β; p value |
| p-tau, ng/L | 0.013 (−0.017, 0.043) 0.081; | 0.058 (0.027, 0.089) 0.365; | −0.008 (0.009, 0.080) 0.017; | 0.146 (−0.031, 0.323) 0.171; |
| (1 = abnormal) | .358 | .707 | .364 (1.42, 2.15) 0.043; | .715 |

Notes: DV, dependent variables; MCI, mild cognitive impairment; WML, white matter lesions; p-tau, phosphorylated tau; CSF, cerebrospinal fluid; Aβ, β amyloid.

* Controlled for different brain pathologies, age, sex, education, and comorbidity.

### Table 5. Multivariable Regression Analyses with Dual Task Cost and Balance as the Dependent Variables in Cognitively Unimpaired and MCI, respectively

| DV | Dual Task Cost (%) | Balance: Figure-of-Eight |
|----|-------------------|--------------------------|
| Cognitively Unimpaired* | MCI* | n = 145 | n = 95 | n = 148 | n = 99 |
| n = 145 | n = 95 | n = 148 | n = 99 |
| WML volume, ml | B (95% CI) β; p value | B (95% CI) β; p value | B (95% CI) β; p value | B (95% CI) β; p value |
| p-tau, ng/L | 0.299 (−0.517, 1.11) 0.068; | 0.470 | −0.455 (−1.84, 0.928) −0.068; | 515 | 0.015 (−0.062, 0.091) 0.034; | 576 | 0.090 (−0.038, 0.218) 0.157; | .164 |
| (1 = abnormal) | .605 | −2.45 (−3.89, −1.01) −0.366; | .001 | −0.005 (−0.073, 0.063) −0.014; | .892 | 0.005 (−0.131, 0.142) 0.009; | .938 |
| CSF Aβ42/40 | 0.719 (−31.6, 33.1) 0.004; | .665 | −13.67 (92.08, 64.75) −0.039; | .730 | 2.80 (−0.261, 5.86) 0.175; | .073 | 0.60 (<−2.60, 11.8) 0.154; | .207 |

Notes: DV, dependent variables; MCI, mild cognitive impairment; TUG, Timed Up & Go; TUG-Cog, TUG with a simultaneous subtraction task; WML, white matter lesions; p-tau, phosphorylated tau; CSF, cerebrospinal fluid; Aβ, β amyloid. Dual task cost (%): (TUG − TUG-Cog)/TUG × 100.

* Controlled for different brain pathologies, age, sex, education, and comorbidity.
Mobility

In the total sample, the volume of WML was the only variable that was independently associated with decreased mobility (ie, TUG) with and without adjusting for other biomarkers. That WML are associated with decreased mobility is in line with two prior studies in older people without dementia (N = 201 and N = 171, respectively) (21,22), although a smaller (N = 80) study found no such association (23). The effect of WML on mobility predominated in the MCI group, that is, despite the fact that we had controlled for MCI when analyzing the total sample.

In the total sample, CSF Aβ or p-tau were not associated with mobility, which is in line with a recent study that used CSF measures (25). Although PET studies that focused on Aβ and mobility (ie, TUG) showed conflicting results (18,24), a study that adjusted for WML load (ie, Fazekas score) showed no association between Aβ and mobility (24). The current findings add to the body of knowledge since our analyses simultaneously considered WML, Aβ, and tau pathology, as well as other factors such as cognitive status.

It needs to be noted that TUG was developed to capture functional mobility (29), and the time to complete TUG does not mimic gait speed. Although TUG includes walking, it also includes rising and sitting down as well as turning. That is, studies that address gait speed are not directly comparable with those focusing on mobility by using TUG. Mobility (ie, as assessed by using TUG) and gait are not interchangeable constructs. This was recently emphasized in a review article that addressed neural correlates of gait, and they therefore excluded studies that used TUG as an outcome measure (43). A recent meta-analysis showed that decreased gait speed was associated with impairment in global cognition (44). We acknowledge that it would have been interesting to include also objective gait measures that tap different components of gait. Not the least as several PET studies have shown an association between amyloid burden and gait, for example, slow gait speed (14–18). In contrast to the current study, these prior studies did not simultaneously consider amyloid and tau pathology as well as WML. A recent cross-sectional study showed that amyloid burden was associated with frailty in older people without dementia, but they did not control for WML and tau pathology (45).

Dual Tasking

Multivariable analyses that only included one type of brain pathology (controlled for age, sex, education, diagnosis, and comorbidity) showed that CSF Aβ42/40 was significantly associated with the dual-task cost. Our findings are in line with a study by Nielsen et al., which showed a correlation between CSF Aβ42 and dual tasking (r = −0.308, p < .01) (33). As in the current study, they used a subtraction task and gave no instructions regarding task prioritization. A small PET study (N = 27) also indicated that Aβ deposition is associated with dual tasking in cognitively healthy older adults (46). However, the current finding was in contrast with the results by Åhman and colleagues (25), who found no association between CSF Aβ42 and the dual-task cost. This is probably due to methodological differences. Although they had a smaller sample size (N = 90 vs. 299 in the current study), it was similar to that of Nielsen and colleagues (N = 86) (33). Instead of using a serial subtraction task, Åhman and colleagues used naming animals and reciting months backward (25). Another methodological discrepancy is that they instructed their participants to prioritize walking over the verbal task, which probably made them walk faster (25). The discrepancy in findings signals that the choice of cognitive task is important and/or whether one provides instructions on task prioritization while dual-tasking.

Importantly, our findings in relation to Aβ pathology did not persist when also adjusting for CSF p-tau and WML. CSF p-tau was the only variable that had an independent effect on dual tasking, which applied both when using TUG-Cog and the dual-task cost as dependent variables. These analyses highlight the importance of controlling for other brain pathologies, especially since Aβ and tau pathologies often occur simultaneously as part of AD. The present results are in agreement with a previous study that found a significant correlation between CSF p-tau and the dual-task cost, that is, in relation to mobility and when using a subtraction task (33). Together, these results indicate that tau pathology is associated with decreased dual-task performance, which is in agreement with recent studies showing that tau pathology is more associated with cognitive impairment than WMLs or Aβ pathology (12,19,20). In other words, this study suggests that tau pathology also has an independent effect on cognitive-motor interference. That is, tau pathology worsens mobility performance while doing a simultaneous cognitive task. The effects of dual tasking depend on the type and amount of executive function involvement, and those with amnestic MCI have higher dual-task costs than those with nonamnestic MCI (47,48). A systematic review that addressed neural correlates of cognitive-motor interference highlighted that a direct comparison between studies was difficult. The prefrontal cortex as well as parietal regions seemed to play an important role in dual tasking (30). The strongest effects for tau pathology on cognition seem to be localized in the lateral and medial parietal cortex and lateral temporal cortex (12).

Despite that we controlled for diagnosis (ie, MCI) in multivariable analyses that included the total sample, the independent effect of tau pathology on dual tasking was only prevalent in the MCI group. This might reflect that the variables had a higher variability in the MCI group, which makes it easier to detect an effect. On the other hand, this could be taken as further support for that tau pathology plays a role in dual-task performance, and that dual-task assessment is of importance in relation to people at risk of developing cognitive decline. It needs to be noted that our findings of dual tasking are only valid when assessing mobility in combination with using a subtraction task.

To the best of our knowledge, this is the first study that simultaneously take into account WML as well as Aβ- and tau pathology in relation to dual tasking in older people without dementia. Our findings have several implications. In the total sample, tau pathology was independently associated with dual tasking irrespective of reporting raw data in relation to TUG-Cog or when calculating the dual-task cost. However, using the dual-task cost instead of the raw data of TUG-Cog might be more specific in relation to AD pathology as indicated by our simple regression analyses (Supplementary Material S1). The volume of WML was then significantly associated with TUG-Cog, which was not the case for the dual-task cost. Both CSF p-tau and amyloid pathology were significantly associated with dual-task cost, which was also the case when adjusting for age, sex, education diagnosis, and comorbidity. In other words, the dual-task cost might be less sensitive to WML and more specific to AD pathology than using the raw data of TUG-Cog. On the other hand, when adjusting for brain pathologies, only p-tau showed an independent effect on the dual-task cost; these findings reflect the importance of taking into account different brain pathologies. All considered, since tau pathology is of relevance for cognitive decline and AD pathology, dual tasking that includes a subtraction task seems important to...
include in the assessment battery. Moreover, the dual-task cost seems valuable to report. A recent consensus statement by the Canadian Consortium on Neurodegeneration in Aging did in fact include dual tasking in the recommended minimum-battery of tests (49).

**Balance**

In the total sample, multivariable analyses showed that CSF Aβ42/40 was independently associated with dynamic balance in older people without dementia. A prior longitudinal PET study showed that higher Aβ burden in putamen was associated with decreased standing (static) balance time in cognitively healthy older adults (17). The current study addressed instead dynamic balance, which is required by most daily activities and transfers. The Figure-of-eight intends to measure dynamic balance (37,38), but one could argue that the timed performance purely mimics walking with a narrow base of support. On the other hand, walking per se challenges balance; this favors including walking when addressing balance control. Balance is indeed a complex construct to assess, and there are numerous clinical instruments available as well as the possibility of using objective measures of postural sway. Interestingly, when using two groups (cognitively unimpaired/MCI), multivariable analyses showed no independent effect of CSF Aβ42/40 on balance; the p value was however .073 in the cognitively unimpaired group, whereas it was .207 in the MCI group. The trend in cognitively unimpaired probably reflects a loss of power when compared with the analysis in the total sample. On the other hand, it may suggest that balance impairments are an early sign of amyloid pathology. This is in line with studies which showed that amyloid burden seems to be associated with a decreased time to first fall in preclinical AD (50), and that an abnormal CSF Aβ42/40 ratio is common in hip fracture patients without dementia (51). Further studies are needed to investigate whether amyloid pathology is independently associated with balance impairments and falls in older nondemented people.

**Additional Methodological Considerations**

A major strength of the current study is that we simultaneously addressed different brain pathologies by using multivariable analyses in relation to mobility, dual tasking and balance. This approach enabled us to study independent effects. Furthermore, we also included both cognitively unimpaired and MCI, and adjusted for diagnostic group to show that the effect was independent of cognitive status, in addition to independent of age, sex, education, and comorbidity. A limitation is the cross-sectional design that does not allow us to draw conclusions about causality of the observed observations. Replicating studies are needed, in order to support or refute the present findings. Future studies may also consider the effects of α-synuclein and TDP-43 pathology, but there are yet no reliable biomarkers for detection of these pathologies in vivo. The current study focused on the total volume of WML, but analyses of different brain regions would have provided a deeper understanding, which also applies in relation to amyloid and tau pathology.

This study focused on mobility, dual tasking, and balance, but there might be other motor aspects of interest. For example, turning ability is considered to be more complex than walking per se (52,53), and it would be interesting in future studies to relate turning to different brain pathologies. Moreover, it was recently stressed that future research on dual tasking should explicitly focus on turning (54). Studies that focus on turning might benefit from also addressing Parkinsonian motor symptoms, as Parkinson’s disease is associated with decreased turning performance (55,56).

**Conclusions**

In older people without dementia, common brain pathologies have different effects on motor-related aspects where WML are independently associated with mobility, tau pathology has the strongest effect on dual tasking and amyloidoid pathology seems to be independently associated with balance. The effects on mobility and dual tasking predominated in the group with MCI, whereas this was not the case for amyloidoid pathology in relation to balance. Although these novel findings need to be confirmed in longitudinal studies, they suggest that different brain pathologies have different effects on mobility, balance, and dual tasking.

**Supplementary Material**

Supplementary data are available at The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences online.

**Funding**

This work was supported by Work by the European Research Council (grant no. 311292 to O.H); the Swedish Research Council (grant no. 2016-00906 to O.H); grant no. 2017-01541 to M.H.N.; the Knut and Alice Wallenberg foundation (grant no. 2017-0383 to O.H); the Marianne and Marcus Wallenberg foundation (grant no. 2015.0125 to O.H); the Strategic Research Area MuItPark (Multidisciplinary Research in Parkinson’s disease) at Lund University; the Swedish Alzheimer Foundation (grant nos. AF-745911 to O.H, AF-843991 to N.M.); the Swedish Brain Foundation (grant nos. FO2019-0326 to O.H and FO2019-0029 to N.M.); the Parkinson foundation of Sweden (grant no. 1127718 to O.H); the Skåne University Hospital Foundation (grant no. 2019-000032 to O.H), and the Swedish federal government under the ALF agreement (grant no. 2018-Projekt0279 to O.H).

**Acknowledgments**

The authors thank the study participants, research nurses, technicians, and physiotherapists involved in the study.

**Author Contributions**

Maria H Nilsson—study design, data acquisition, analysis and interpretation of data, statistical analysis, drafting the manuscript, and obtaining of funding. Gro Gujord Tangen—study design, data acquisition, and critical revision of manuscript. Oskar Hansson—study design, interpretation of data, statistical analysis, drafting the manuscript, and obtaining of funding. Erik Stomrud—data acquisition, provided input on design, and critically revised the manuscript. Sebastian Palmqvist, Danielle van Westen, and Niklas Mattsson provided input on design and critically revised the manuscript.

**Conflict of Interest**

M.H.N., G.G.T., S.P., D.W., N.M., and E.S. report no disclosures relevant to the manuscript. O.H. has acquired research support (for the institution) from Roche, GE Healthcare, Biogen, AVID Radiopharmaceuticals and Euroimmun. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Biogen and Roche.

**Data Availability**

Anonymized data will be shared by request from a qualified academic investigator for the sole purpose of replicating procedures and results presented in the article and as long as data transfer is in agreement with EU legislation on
the general data protection regulation and decisions by the Ethical Review Board of Sweden and Region Skåne.

Impact Statement

What was already known on this topic: Previous PET studies have shown an association between Aβ burden and decreased gait performance in older people without dementia, but none of these simultaneously addressed WML and tau pathology. WML have been associated with decreased mobility (ie, TUG), whereas PET studies that focused on Aβ and mobility have shown conflicting results. WML have also been associated with balance impairments and falls, but there is limited knowledge in relation to Aβ- and tau pathology. The latter applies also for dual-task performance.

What this study adds: This study provides novel knowledge by using multivariable analyses that take into account WML as well as markers of Aβ- and tau pathology in relation to mobility, dual tasking, and balance performance. Importantly, we also controlled for age, sex, education, diagnosis (MCI), and comorbidity. Our main findings suggest that WML volume is independently associated with decreased mobility, whereas tau pathology is independently associated with worse dual-task performance (ie, in relation to mobility and when adding a cognitive subtraction task). Moreover, our results indicate that Aβ pathology may be of importance for dynamic balance in older people without dementia.

References

1. Mielke MM, Roberts RO, Savica R, et al. Assessing the temporal relationship between cognition and gait: slow gait predicts cognitive decline in the Mayo Clinic Study of Aging. J Gerontol A Biol Sci Med Sci. 2013;68:929–937. doi:10.1093/gerona/gls256
2. Vergheze J, Holtzer R, Wang C, Krajczi T, Barzilai N, Lipton RB. Role of APOE genotype in gait decline and disability in aging. J Gerontol A Biol Sci Med Sci. 2013;68:1395–1401. doi:10.1093/gerona/glt115
3. Vergheze J, Ayers E, Barzilai N, et al. Motoric cognitive risk syndrome: multicenter incidence study. Neurology. 2014;83:2278–2284. doi:10.1212/01.wnl.0000459383.04084.53
4. Montero-Odasso M, Speechley M, Muir-Hunter SW, et al. Motor and cognitive trajectories before dementia: results from gait and brain study. J Am Geriatr Soc. 2018;66:1676–1683. doi:10.1111/jgs.15341
5. Wardlaw JM, Smith EF, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12:822–838. doi:10.1016/S1474-4422(13)70124-8
6. Blennow K, Mattsson N, Schöll M, Hansson O, Zetterberg H. Amyloid biomarkers in Alzheimer’s disease. Trends Pharmacol Sci. 2015;36:297–309. doi:10.1016/j.tips.2015.03.002
7. Janelidze S, Pannem J, Mikulski A, et al. Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment. JAMA Neurol. 2017;74:1492–1501. doi:10.1001/jamaneurol.2017.2814
8. Schöll M, Maass A, Mattsson N, et al. Biomarkers for tau pathology. Mol Cell Neurosci. 2019;97:18–33. doi:10.1016/j.mcn.2018.12.001
9. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes of dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367:795–804. doi:10.1056/NEJMoA1202753
10. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Biomarkers for tau pathology. Exp Gerontol. 2011;46:577–588.
11. Ossenkoppele R, Rabinovici GD, Smith R, et al. Discriminative accuracy of [18F]Flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2018;320:1151–1162. doi:10.1001/jama.2018.12917
12. Ossenkoppele R, Smith R, Ohlsson T, et al. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. Neurology. 2019;92:e601–e612. doi:10.1212/WNL.000000000006875
13. Storjohann SJ, Ewing AJ, Kukull WA, et al. Discriminant validity of Aβ-amyloid to gait speed. Neurology. 2016;86:36–43. doi:10.1212/WNL.0000000000022335
14. Del Campo N, Payoux P, Dijabali A, et al. Relationship of regional brain Aβ-amyloid to gait speed. Neurology. 2016;86:36–43. doi:10.1212/WNL.0000000000022335
15. Nadkarni NK, Perera S, Snitz BE, et al. Association of brain Amyloid-β with slow gait in elderly individuals without dementia: influence of cognition and apolipoprotein E r4 genotype. JAMA Neurol. 2017;74:82–90. doi:10.1001/jamaneurol.2016.3474
16. Wennergberg AM, Lesnicz TG, Schwarz CG, et al. Longitudinal association between brain amyloid-beta and gait in the mayo clinic study of aging. J Gerontol A Biol Sci Med Sci. 2018;73:1244–1250. doi:10.1093/gerona/glz240
17. Tian Q, Resnick SM, Studenski SA. Olfaction is related to motor function in older adults. J Gerontol A Biol Sci Med Sci. 2017;72:1067–1071. doi:10.1093/gerona/glw222
18. Yoon DH, Lee JY, Shin SA, Kim YK, Song W. Physical frailty and amyloid-beta deposits in the brains of older adults with cognitive frailty. J Clin Med. 2017;6:169. doi:10.3390/jcm7070169
19. Svaninsson AL, Stomrud E, Insel PS, Mattsson N, Palmqvist S, Hansson O. Aβ-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly. Sci Rep. 2019;9:11180. doi:10.1038/s41598-019-47638-y
20. Hanseuu BJ, Betensky RA, Jacobs HI, et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 2019;76(8):915–924. doi:10.1001/jamaneurol.2019.1424 [Epub ahead of print]
21. Hashimoto M, Takashima Y, Uchino A, Yuzuriha T, Yao H. Dual task walking reveals cognitive dysfunction in community-dwelling elderly subjects: the Sefuri brain MRI study. J Stroke Cerebrovasc Dis. 2014;23:1770–1775. doi:10.1016/j.jstrokecerebrovasdis.2014.05.008
22. Allali G, Annweiler C, Predovan D, Bherer L, Beauchet O. Brain volume changes in gait control in patients with mild cognitive impairment compared to cognitively healthy individuals; GaIT study results. Exp Gerontol. 2016;76:72–79. doi:10.1016/j.exger.2015.12.007
23. Kose Y, Ikenaga M, Yamada Y, et al. Timed Up and Go test, atrophy of medial temporal areas and cognitive functions in community-dwelling older adults with normal cognition and mild cognitive impairment. Exp Gerontol. 2016;85:81–87. doi:10.1016/j.exger.2016.09.019
24. Doo E, Hwang GR, Son SI, et al. Cerebral Amyloid-β deposition is associated with impaired gait speed and lower extremity function. Alzheimers Dis. 2019;71(s1):S51–S59. doi:10.3233/JAD-180848
25. Ahmán HB, Giedraitis V, Cedervall Y, et al. Dual-task performance and neurodegeneration: correlations between timed up-and-go dual task outcomes and Alzheimer’s disease cerebrospinal fluid biomarkers. Alzheimers Dis. 2019;71(s1):S75–S83. doi:10.3233/JAD-181265
26. Kreisel SH, Blahak C, Bäzner H, et al. Deterioration of gait and balance over time: the effects of age-related gait progresses of the LADIS study. Cerebrovasc Dis. 2013;35:544–553. doi:10.1159/000350725
27. Murray ME, Senjem ML, Petersen RC, et al. Functional impact of white matter hyperintensities in cognitively normal elderly subjects. Arch Neurol. 2010;67:1379–1385. doi:10.1001/archneurol.2010.280
28. Svistav H, Beare R, Blizard L, et al. Cerebral white matter lesions, gait, and the risk of incident falls: a prospective population-based study. Stroke. 2009;40:175–180. doi:10.1161/STROKEAHA.108.524355
29. Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39:142–148. doi:10.1111/j.1532-5415.1991.tb01616.x
30. Leone C, Fyys P, Momadjian L, D’Amico E, Zappia M, Patti F. Cognitive-motor dual-task interference: a systematic review of neural correlates. Neurosci Biobehav Rev. 2017;75:348–360. doi:10.1016/j.neubiorev.2017.01.010
31. David JP, Ferrat E, Parson J, et al. White matter lesions: prevalence and clinical phenotype in asymptomatic individuals aged ≥50 years. Dement Geriatr Cogn Disord. 2016;42:159–168. doi:10.1159/000448991
32. Ghanavati T, Smitt MS, Lord SR, et al. Deep white matter hyperintensities, microstructural integrity and dual task walking in older people. Brain Imaging Behav. 2018;12:1488-1496. doi:10.1007/s11682-017-9787-7
33. Nielsen MS, Simonsen AH, Siemsa V, Hasselbalch SG, Hoegh P. The diagnostic and prognostic value of a dual-tasking paradigm in a memory clinic. J Alzheimers Dis. 2018;61:1189–1199. doi:10.3233/JAD-161310
34. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:533–562. doi:10.1016/j.jalz.2018.02.018
35. Berglund G, Elmstahl S, Janzon L, Larsson SA. The Malmo Diet and cancer study. Design and feasibility. J Intern Med. 1993;233:45–51. doi:10.1111/j.1365-2796.1993.tb06647.x
36. Montero-Odasso M, Muir SW, Speechley M. Dual-task complexity affects gait in people with mild cognitive impairment: the interplay between gait variability, dual tasking, and risk of falls. Arch Phys Med Rehabil. 2012;93:293–299. doi:10.1016/j.apmr.2011.08.026
37. Johansson G, Jarnlo G-B. Balance training in 70-year-old women. Physiotherapy Theory and Practice. 1991;7:121–125. doi:10.3109/09593989109106962
38. Jarnlo G-B, Nordell E. Reliability of the modified Figure of eight—a balance performance test for elderly women. Physiotherapy Theory and Practice. 2003;19:35–43. doi:10.1080/095939803079769
39. Palmqvist S, Zetterberg H, Blennow K, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 2014;71:1282–1289. doi:10.1001/jamaneurol.2014.1358
40. Bertens D, Tijms BM, Schelten P, Tenissen CE, Visser PJ. Unbiased estimates of cerebrospinal fluid β-amyloid 1-42 cutoffs in a large memory clinic population. Alzheimers Res Ther. 2017;9:8. doi:10.1186/s13195-016-0233-7
41. Benaglia T, Chauveau D, Hunter DR, Young D. mixtools: an R package for analyzing mixture models. J Stat Softw. 2009;32:1–29. doi:10.18637/jss.v032.i06
42. Schmidt P, Gaser C, Arsic M, et al. An automated tool for detection of FLAIR-hyperintense white-matter lesions in multiple sclerosis. Neuroimage. 2012;59:3774–3783. doi:10.1016/j.neuroimage.2011.10.032
43. Wilson J, Allcock L, McArdle R, Taylor JP, Rochester L. The neural correlates of discrete gait characteristics in ageing: a structured review. Neurosci Biobehav Rev. 2019;100:344–369. doi:10.1016/j.neubiorev.2018.12.017
44. Peel NM, Alapatt LJ, Jones LV, Hubbard RE. The association between gait speed and cognitive status in community-dwelling older people: a systematic review and meta-analysis. J Gerontol A Biol Sci Med Sci. 2019;74:943–948. doi:10.1093/gerona/glz009
45. Maltais M, De Souto Barreto P, Hooper C, Payoux P, Rolland Y, Vellas B, MAPT/DNA Study Group. Association between brain β-amyloid and frailty in older adults. J Gerontol A Biol Sci Med Sci. 2019;74:1747–1752. doi:10.1093/gerona/glz009
46. Nadkarni NK, Lopez OL, Perera S, et al. Cerebral amyloid deposition and dual-tasking in cognitively normal, mobility unimpaired older adults. J Gerontol A Biol Sci Med Sci. 2017;72:431–437. doi:10.1093/gerona/glw211
47. Forte R, Pesce C, Di Baldassarre A, et al. How older adults cope with cognitive complexity and environmental constraints during dual-task walking: the role of executive function involvement. Int J Environ Res Public Health. 2019;16(10):1835. doi:10.3390/ijerph16101835
48. Montero-Odasso M, Otenig-Aamoako A, Speechley M, et al. The motor signature of mild cognitive impairment: results from the gait and brain study. J Gerontol A Biol Sci Med Sci. 2014;69:1415–1421. doi:10.1093/gerona/glu153
49. Montero-Odasso M, Almeida QJ, Bherer L, et al. Consensus on shared measures of mobility and cognition: from the Canadian Consortium on Neurodegeneration in Aging (CCNA). J Gerontol A Biol Sci Med Sci. 2019;74:897–909. doi:10.1093/gerona/gly148
50. Stark SL, Roe CM, Grant EA, et al. Preclinical Alzheimer disease and risk of falls. Neurology. 2013;81:437–443. doi:10.1212/WNL.0b013e31829d8599
51. Oh ES, Blennow K, Bigelow GE, et al. Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia. PLoS One. 2018;13:e0204695. doi:10.1371/journal.pone.0204695
52. Odonkor CA, Thomas JC, Holt N, et al. A comparison of straight- and curved-path walking tests among mobility-limited older adults. J Gerontol A Biol Sci Med Sci. 2013;68:1532–1539. doi:10.1093/gerona/glt060
53. Mirelman A, Weiss A, Buchman AS, Bennett DA, Giladi N, Hausdorff JM. Association between performance on Timed Up and Go subtasks and mild cognitive impairment: further insights into the links between cognitive and motor function. J Am Geriatr Soc. 2014;62:673–678. doi:10.1111/jgs.12734
54. Bayot M, Dujardin K, Tard C, et al. The interaction between cognition and motor control: a theoretical framework for dual-task interference effects on posture, gait initiation, gait and turning. Neurophysiol Clin. 2018;48:361–375. doi:10.1016/j.nuclphysci.2018.10.003
55. Herman T, Weiss A, Brozgol M, Giladi N, Hausdorff JM. Identifying axial symptoms of cerebrospinal fluid β-amyloid 42: detection in clinical practice using cerebrospinal fluid β-amyloid 1-42 cutoffs in a large memory clinic population. J Neurol Phys Ther. 2014.1358